semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 7.0-17.0,  Asthma Allergic Asthma Non-allergic Asthma children age 7-17 years old with the diagnosis of allergic asthma or non-allergic asthma (n=102  history of immunodeficiency, mastocytosis chronic abnormal conditions of the skin, liver or kidney neoplastic disease movement or neurologic disorders active eczema on the forearms at the time of study history of a previous anaphylactic episode evidence of pregnancy (by urinary hCG) or lactation at the time of the study
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Atopic Asthma Male and female volunteers 18 through 65 years of age Females must not be actively seeking pregnancy, must be using adequate and effective contraception General good health Mild to moderate, stable, allergic asthma History of episodic wheeze and shortness of breath; FEV1 at baseline at least 70% of the predicted value Able to understand and give written informed consent and has signed a written informed consent form approved by the investigator's REB Positive methacholine challenge Positive skin-prick test to common aeroallergens (including cat, dust mite, grass, pollen) Positive allergen-induced airway bronchoconstriction (a fall in FEV1 of at least 20% from baseline)  A worsening of asthma or a respiratory tract infection within 6 weeks preceding study entry History of clinically significant hypotensive episodes or symptoms of fainting, dizziness, or lightheadedness History or symptoms of clinically significant autoimmune disease History of clinically significant hematologic abnormality, including coagulopathy Be pregnant or lactating Use of corticosteroids, immunosuppressives, anticoagulants (warfarin or heparin) within 28 days prior to randomization into the study Use of nonsteroidal anti-inflammatory drugs (NSAIDs) within 48 hours of dosing or aspirin with 7 days of dosing Have chronic use of any other medication for treatment of allergic lung disease other than short and intermediate-acting ß2-agonists or ipratropium bromide Use of caffeine-containing products or medications for 12 hours or alcohol or over the counter drugs including aspirin, cold and allergy medications for 48 hours or inhaled bronchodilators for 8 hours prior to methacholine and allergen challenges
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 12.0-999.0,  Asthma Signed informed consent Outpatient at least 12 years of age with diagnosis of asthma at least 12 weeks before first visit Both genders; females of child bearing potential must be willing to use appropriate contraception during the study Pre-bronchodilator FEV1 of at least 60% predicted FEV1 reversibility of at least 12% and 200mls Current asthma therapy that includes a non-corticosteroid controller and/or short-acting beta agonist  History of life-threatening asthma exacerbation within the past 10 years Asthma exacerbation requiring treatment with oral corticosteroids within the last 3 months or that required overnight hospital stay within 6 months Current or recent respiratory infection or current oral candida infection Presence of another significant respiratory disease or medical condition that is not controlled or that could affect subject safety or study outcome Known or suspected allergy to study drug or materials Taking another investigational medication or prohibited medication during the study Previous treatment with inhaled fluticasone furoate in a phase II or III study Current smokers or former smokers with significant tobacco exposure Children in Care
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 12.0-999.0,  Asthma Signed informed consent Outpatient at least 12 years of age with a diagnosis of asthma at least 12 weeks prior to first visit Both genders; females of child bearing potential must be willing to use appropriate contraception during the study Pre-bronchodilator FEV1 of at least 60% predicted FEV1 reversibility of at least 12% and 200ml Current asthma therapy that includes a non-corticosteroid controller and/or short acting beta-agonist  History of life-threatening asthma exacerbation with the past 10 years Asthma exacerbation requiring oral corticosteroids within the past 3 months or overnight hospital stay within the past 6 months Current or recent respiratory infection or current oral candida infection Presence of a significant respiratory disease or other medical condition that is uncontrolled or that could affect subject safety or study outcome Known or suspected allergy to study medication or materials Taking another investigational medication or prohibited medication during the study Current smokers or former smokers with significant tobacco exposure Previous treatment with fluticasone furoate in a phase II or III study Children in Care
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Asthma The patient provides written informed consent to participate in the study 2. Male or female patient aged 18 to 65 years 3. Documented diagnosis of asthma 4. Forced Expiratory Volume in One Second (FEV1) between 50% and 80% of the predicted value 5. Patient judged by the investigator to be in otherwise good stable health based on medical history, physical examination, and routine laboratory data 6. Female participants must have a negative pregnancy test at screening visit 7. Males must agree to use barrier contraception while on study medication and for 90 days after taking the last dose of study medication  Pregnant or lactating women 2. Female subjects on hormone replacement therapy or hormonal contraceptives 3. Suffering from relevant lung diseases (other than asthma) causing impairment in lung function 4. Past smoker with a history of ≥10 pack per year or current smoker 5. Recent change in the patient's usual asthma treatment 6. Patients with risk factors for asthma exacerbation during the study, including (any of the following) Current requirement for > 8 puffs per day of reliever medication Hospitalization for asthma Treatment with systemic corticosteroid therapy within 3 months 7. Evidence of current or recent neoplastic disease 8. Clinically significant cardiovascular, haematological, endocrine, neurological, gastrointestinal, psychiatric, metabolic, immunologic, infectious, hepatic, renal, gynaecological disease or other condition that the investigator considers detrimental to the patient's participation in the study or that may prevent the successful completion of the study 9. Positive serology for an infectious disease (including hepatitis B or C) at screening and known case of human immunodeficiency virus [HIV] 10. Patients who have been hospitalized for any psychiatric illness in the past year, or are diagnosed with major depression 11. Clinically significant ECG Abnormality at baseline 12. Patients with documented or suspected or current history of alcohol and drug abuse 13. Patients who have undergone lung surgery in the previous year 14. Participation in an investigational drug trial during 30 days preceding screening
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Asthma Physician diagnosis of asthma, as per the Global Initiative for Asthma (GINA) (2009) guidelines, and currently prescribed Inhaled Corticosteroids (ICS) therapy Patients with a pre-bronchodilator Forced Expiratory Volume in 1 second (FEV1) value of 40% to 80% of individual predicted value Patients should be allergic or atopic, as diagnosed historically or prior to entry into the study Patients who are demonstrated to have reversible airway obstruction or airways hyper-reactivity or have shown either of such responses in previous test(s) within the last year An Asthma Control Questionnaire (ACQ) score ≥ 1.5 at randomization  Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test (> 5 mIU/mL) Patients with serious co-morbidities including uncontrolled diabetes (HbA1c≥8%), heart failure, cancer, neurodegenerative diseases, rheumatoid arthritis and other autoimmune diseases, other lung diseases including chronic bronchitis, chronic obstructive pulmonary diseases or emphysema or other conditions characterized by eosinophilia and pulmonary symptoms (i.e. Churg-Strauss syndrome, allergic bronchopulmonary aspergillosis, eosinophilic pneumonia, etc.) Acute illness other than asthma at the start of the study History of life-threatening asthma, including a history of significant hypercarbia (pCO2>45mmHg), prior intubation, respiratory arrest, or seizures as a result of asthma Patients who have had a respiratory tract infection within 4 weeks of the screening visit. Patients who develop a respiratory tract infection between screening and the randomization visit must be screen failed, and may be permitted to re-enroll at a later date Current smokers or ex-smokers who stopped smoking within 6 months prior to screening or have a smoking history of ≥ 10 pack years
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 40.0-999.0,  COPD COPD Exacerbation Lung Diseases Respiratory Disorders Pulmonary Disease Chronic Obstructive Lung Diseases Chronic Obstructive Airway Disease Male or female patients at least 40 years of age History of COPD (according to Global Initiative for Chronic Obstructive Lung Disease [GOLD] 2010) for at least 12 months prior to Screening (Visit 1) associated with chronic productive cough for 3 months in each of 2 consecutive years (with other causes of productive cough excluded). Only patients with chronic bronchitis will be included (concomitant emphysema is permitted) Forced expiratory volume after 1 second (FEV1)/forced vital capacity (FVC) ratio (postbronchodilator) < 70% at Screening (Visit 1) FEV1 (postbronchodilator) ≤ 50% of predicted at Screening (Visit 1) At least two documented moderate or severe COPD exacerbations within 12 months prior to Screening (Visit 1) Patients must be on FDC LABA/ICS treatment ≥ 3 months prior to Screening (Visit 1) Former smokers (defined as smoking cessation at least 1 year ago) or current smokers (including patients who ceased smoking within the past year) both with a smoking history of at least 20 pack-years  Moderate or severe COPD exacerbation and/or COPD exacerbations treated with antibiotics or systemic glucocorticosteroids within 4 weeks of Screening (Visit 1) (ie, patients must be clinically stable) Known alpha-1-antitrypsin deficiency Current diagnosis of asthma (either controlled or uncontrolled) (Note: History of childhood asthma is not exclusionary.) Body mass index (BMI) ≥ 45 kg/m2 Patients with a history (within 5 years) or current diagnosis of cancer other than basal or squamous cell skin cancer
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 5.0-60.0,  Asthma Have physician diagnosed asthma 2. Male or female between ages 5 through 60 years 3. Have persistent asthma as assessed by daily use of "controller" medication 4. Receive continuity care at practice where enrolled. 5. Not have been in ICU for asthma ever 6. Do not require daily or every other day oral steroids for asthma control  Cannot read and speak English 2. Child refuses assent
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Asthma Main 1. Patient with severe asthma and already treated with oral corticosteroids at a minimal daily dose of 7.5 mg prednisone or equivalent for at least 3 months prior to screening visit 2. Patient treated with oral corticosteroids during at least one period of 21 days, from 1 year prior to screening to 3 months before screening 3. Patient with no significant change in the regular asthma medication, no severe asthma exacerbation for at least 4 weeks prior to screening visit 4. Non-smoker patient for at least 1 year and with a prior tobacco consumption < 10 packs/year Main  Patient with active lung disease other than asthma (e.g. chronic bronchitis) 2. Female patient who is pregnant or lactating 3. Asthmatic patient still exposed to allergens or to triggering factors influencing asthma control 4. Patient with history of acute infectious sinusitis or respiratory tract infection within 4 weeks prior to screening visit
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 12.0-56.0,  Asthma KPSC members at time of uncontrolled event: 1. 12-56 years of age 2. Continuously enrolled and with pharmacy benefit for the past year 3. Dispensed inhaled corticosteroid (ICS) in the past 6 months. 4. Uncontrolled asthma: defined within the past year Impairment cohort: 7th short-acting beta-agonist (SABA) canister dispensed and/or Risk (exacerbation) cohort: 2nd oral corticosteroid (OCS)dispensing with provider asthma exacerbation encounter within 2 days and at least 1 month after the first OCS dispensing  Patients with chronic obstructive lung disease emphysema cystic fibrosis chronic bronchitis bronchiectasis Churg Strauss Wegener's sarcoidosis pulmonary hypertension or other clinically relevant non-asthma pulmonary disorder such as autoimmunity immune deficiency
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 5.0-18.0,  Duchenne Muscular Dystrophy for boys with DMD: 1. Ambulatory and non-ambulatory males (ages 5-18) previously diagnosed with DMD based on clinical features with onset of symptoms before age five elevated serum creatine kinase level or absence of dystrophin expression, as determined by immunostain or western blot (<2%) and/or DNA confirmation of a dystrophin mutation. 2. Subjects will not be excluded based on corticosteroid treatment for age matched controls: 1. Ambulatory males (ages 5-18) without disease or injury to the lower extremities  Males with a contraindication to an MR examination 2. Males with unstable medical problems 3. Males who are not able to cooperate during testing 4. Males with a secondary condition that may impact muscle metabolism, muscle function or functional ability (i.e. cerebral palsy, endocrine disorders, mitochondrial disease) 5. Healthy boys who participate in competitive sports specific training in excess of 8 hours per week. Participation in multiple recreational sports activities is not an exclusion
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Dyspnoea Chest Pain Cough All 4 of the following must be present: 1. The sonographic examination can be performed before or within 1 hour after the primary evaluation 2. Patient is 18 years or older 3. Patient able and willing to give informed consent 4. One ore more of the following symptoms or clinical findings at admission to the emergency department Respiratory rate > 20 breaths per minute Saturation < 95% Oxygen therapy initiated The patient has a principal complaint of dyspnoea The patient has a principal complaint of coughing The patient has a principal complaint of chest pain  One of the following: 1. The sonographic examination can not be performed within 1 hour after the primary evaluation 2. The patient is 17 years or younger 3. The patient not able or willing to give informed consent